Regulatory strategy

Regulatory strategy, submission management, global market access for medical devices.

Regulatory strategy

Gather product info (intended use, classification/risk, technology, target markets/timeline) → identify regulations per market → determine optimal pathway → timeline + milestones → resources + budget → risks + mitigation → stakeholder approval.

FDA pathway selection:

FDA submissions

510(k): confirm predicate (K-number) + substantial-equivalence argument + no new intended use/tech → pre-sub (Q-Sub) if needed → compile package (cover letter, admin, device description, intended use, SE comparison table, performance testing, biocompatibility ISO 10993-1, software IEC 62304 + cybersecurity, labeling, summary) → RTA check → eCopy → submit via ESG + fee → respond to AI/RTA within deadlines. SE table columns: characteristic · predicate · subject device · same? · notes (new technological characteristics must not raise new safety/effectiveness questions — back with bench data). PMA: confirm Class III / no predicate → IDE clinical study → pre-sub → 5-volume submission (admin/description/manufacturing · nonclinical · clinical · labeling · manufacturing+sterilization) → address deficiencies → facility inspection. Common deficiencies: weak SE comparison · incomplete test protocols · missing biocompatibility endpoints · inadequate software hazard analysis · inconsistent labeling claims.

EU MDR CE marking

Confirm classification (Annex VIII) → conformity route by class (I self-declaration · IIa/IIb NB · III full NB) → engage Notified Body → compile Annex II technical documentation (device description + UDI · design/manufacturing · GSPR checklist mapped to evidence · benefit-risk + ISO 14971 risk file · V&V · post-market surveillance plan · Annex XIV clinical evaluation report) → ISO 13485 QMS → submit to NB → coordinate audit → CE certificate + Declaration of Conformity + EUDAMED registration. GSPR row: ref · requirement · standard/guidance · evidence document · status. NB selection: designation scope, capacity/timeline, technology experience, geography, fee transparency, responsiveness.

Global market access

Sequence markets to leverage evidence: Phase 1 FDA + EU (reference) → Phase 2 recognition markets (Canada MDSAP, Australia) → Phase 3 major (Japan, China) → Phase 4 emerging. Build a master technical file + localization plan; single-source the core (risk mgmt, clinical data with bridging, ISO 13485 cert) and localize labeling/IFU (translation, local symbols ISO 15223-1).

Regulatory intelligence

Monitor FDA Federal Register (daily), device database (weekly), EU Official Journal + MDCG, NB communications, ISO/IEC (quarterly). Assess relevance → impact (timeline, resources, product changes) → compliance action plan with owners + dates → implement within effective-date window.

KPIs

First-time approval rate >85% · on-time submission >90% · review-cycle compliance >95% · regulatory hold time <20%.

Escalation

Submission rejection → VP Regulatory (root cause + strategy revision) · major deficiency → Director (cross-functional team) · timeline at risk → Management · safety signal → Executive (immediate containment + reporting).